使用重组组织型纤溶酶原激活剂进行全身溶栓治疗急性危及生命的Blalock-Taussig分流梗阻。

Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction.

作者信息

Diaz Franco, Sasser William C, Law Mark A, Alten Jeffrey A

机构信息

Division of Pediatric Critical Care Medicine, Section of Cardiac Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Division of Pediatric Cardiology, Section of Cardiac Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Indian J Crit Care Med. 2016 Jul;20(7):425-7. doi: 10.4103/0972-5229.186248.

DOI:10.4103/0972-5229.186248

PMID:27555699

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4968067/

Abstract

Modified Blalock-Taussig shunt (mBTS) obstruction can be life-threatening, especially when it represents the only source of pulmonary blood flow. Current therapeutic options to reverse obstruction include surgical shunt revision/replacement, interventional endovascular procedures including balloon angioplasty and/or stent placement, and a combination of local and systemic thrombolytic therapy. We report two cases of acute mBTS thrombosis successfully treated with systemic recombinant tissue plasminogen activator in infants convalescing after cardiac surgery when the clinical status and resources precluded traditionally described rescue therapies.

摘要

改良布莱洛克-陶西格分流术（mBTS）梗阻可能危及生命，尤其是当它是肺血流的唯一来源时。目前用于逆转梗阻的治疗选择包括手术分流术修正/置换、介入性血管内手术，如球囊血管成形术和/或支架置入，以及局部和全身溶栓治疗的联合应用。我们报告了两例急性mBTS血栓形成的病例，在心脏手术后康复的婴儿中，当临床状况和资源排除了传统描述的挽救治疗方法时，成功地使用了全身重组组织型纤溶酶原激活剂进行治疗。